SavedAdd your journal

Journals / Türk Oftalmoloji Dergisi / 2003 / Cilt: 33 - Sayı: 3

The efficacy of topical 0.1% cyclosporine A in the treatment of dry eye disease associated with Sjögren syndrome

Sjögren sendromuna bağlı kuru göz hastalığında topikal %0.1 siklosporin A tedavisinin etkinliği

Ebru TOKER
Haluk KAZOKOĞLU
Nur ACAR
Pages
324–330
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Schirmer I test, Schirmer test with anesthesia, and tear break-up time increased significantly at 3 months and 6 months compared with the baseline scores in eyes treated with CsA (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the efficacy of topical 0.1% cyclosporine A (CsA) aqueous solution in the treatment of dry eye disease in Sjögren syndrome (SS) patients.
📊
Key Findings & Data:The patients used 0.1% CsA prepared in artificial tears in one eye and the other eye received artificial tears (vehicle) only.
💡
Conclusion & Impact:Schirmer I test, Schirmer test with anesthesia, and tear break-up time increased significantly at 3 months and 6 months compared with the baseline scores in eyes treated with CsA (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the efficacy of topical 0.1% cyclosporine A (CsA) aqueous solution in the treatment of dry eye disease in Sjögren syndrome (SS) patients. Methods: Twenty-five patients diagnosed as primary or secondary SS with dry eye disease were enrolled to this study. The patients used 0.1% CsA prepared in artificial tears in one eye and the other eye received artificial tears (vehicle) only. Lacrimal function tests including Schirmer I test, Schirmer test with anesthesia, tear break-up time and flourescein, and rose bengal staining of the ocular surface were recorded at baseline and 1,3, and 6 months after the initiation of treatment. Results: At 3 and 6 months, treatment with CsA gave significantly greater improvement than artificial tears (vehicle) in Schirmer I test (p=0.03 and p=0.008, respectively), Schirmer test with anesthesia (p=0.01 and p=0.001, respectively), tear breakup-time (p=0.04 and p=0.001, respectively), flourescein (p=0.03 and p-0.008, respectively) and rose bengal staining scores (p=0.045 and p=0.005, respectively) of ocular surface. Schirmer I test, Schirmer test with anesthesia, and tear break-up time increased significantly at 3 months and 6 months compared with the baseline scores in eyes treated with CsA (p

Özet

Amaç: Sjögren sendromlu (SS) kuru göz hastalarında topikal %0.1 siklosporin A (CsA) tedavisinin etkinliğini değerlendirmek. Gereç ve Yöntem: Çalışmaya 25 primer veya sekonder SS'lu kuru göz hastası dahil edildi. Hastaların bir gözlerine suni gözyaşı içinde hazırlanmış %0.1 CsA damlası, diğer gözlerine ise taşıyıcı olarak kullanılan suni gözyaşı damlası ile tedaviye başlandı. Tedavi öncesinde ve tedavinin L, 3. ve 6. ayında hastaların kuru göz bulguları Schirmer I testi, anestezili Schirmer testi, gözyaşı kırılma zamanı (GKZ), flouresein ve rose bengal ile oküler yüzey boyanma skorları ile değerlendirildi. Bulgular: CsA tedavisi alan gözlerde, tedavinin 3. ve 6. ayında Schirmer I testi (sırasıyla, p=0.03 ve p=0.008), anestezili Schirmer testi (sırasıyla, p=0.01 ve p=0.001), GKZ (sırasıyla, p=0.04 ve p=0.001), flouresein ile korneal boyanma (sırasıyla, p=0.03 and p=0.008) ve rose bengal skorlarında (sırasıyla, p=0.045 ve p=0.005) suni gözyaşı alan gözlere göre daha fazla dü-zelme olduğu saptandı. Tedavinin 3.ve 6.ayında, CsA tedavisi alan gözlerde Schirmer I testi, anestezili Schirmer testi ve GKZ'ında tedavi öncesine göre anlamlı artış saptandı (p

🔖

Cite This Article

TOKER, E., KAZOKOĞLU, H., ACAR, N. (2022). The efficacy of topical 0.1% cyclosporine A in the treatment of dry eye disease associated with Sjögren syndrome. Türk Oftalmoloji Dergisi, Cilt: 33 - Sayı: 3, 324–330. https://ajindex.com/articles/638985

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lemp ME: Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. CLAO J 1995; 21: 221-232
  2. Pflugfelder SC, Wilhelmus KR, Osata MS, Matoba AY, Font RL: The autoimmune nature of aqueous tear deficiency. Ophthalmology 1986; 93: 1513-1517
  3. Pepose JS, Akata RF, Pflugfelder SC, Worgt W: Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjögren's syndrome. Ophthalmology 1990; 97: 1599-1605
  4. Matsumoto I, Tsubota K, Satake Y, Kita Y, Matsumura R, Murata H, Namekawa T: Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjögren's syndrome. J Clin Invest 1996; 97:1966-1977
  5. Tischer M, Yaron I, Geyer O, Shirazi I, Naftaliev E, Yaron M: Elevated tear interleukin-6 levels in patients with Sjögren's syndrome. Ophthalmology 1998; 105: 2327- 2329
  6. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D: Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. CurrEyeRes 1999; 19: 201-211
  7. Damato BE, Allan D, Murray SB, Lee WR: Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease. Br J Ophthalmol 1984; 68: 674-680
  8. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder S. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998;17:584-589
  9. Azzarolo AM, Mircheff AK, Kaswan RL, Stanczyk FZ, Gentscein, Becker L, Nassir B, Warren DW: Androgen support of lacrimal gland function. Endocrine 1997; 6: 39-45
  10. Mircheff AK, Warren D W, Wood RL: Hormonal support of lacrimal function, primary lacrimal deficiency, autoimmunity and peripheral tolerance in the lacrimal gland. Ocul Immunol Inflamm 1996; 4: 145-172
  11. Laibovitz RA, Solch S, Adriano K, O'Connell M, Silverman MH: Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea 1993; 124:311-323
  12. Power WJ, Mullaney P, Farrell M, Collum LM: Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjögren's syndrome. Cornea 1993; 12: 507-511
  13. Gündüz K, Özdemir Ö: Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren's syndrome. Acta Ophthalmol 1994; 72: 438-442
  14. Inoue K, Amano S, Kimura C, Sato S, Fujita N, Kagaya F, Kaji Y, Oshika T, Tsuru T, Araise M: Longterm effects of topical cyclosporine A treatment a